IncobotulinumtoxinA in clinical literature.

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

IncobotulinumtoxinA is the third neurotoxin type A to be approved for aesthetic use in the United States. Because incobotulinumtoxinA has been in use in Europe for some time, the clinical literature is fairly replete with references to its properties and characteristics, as well as its safety and efficacy. In North America, 2 pivotal trials, referred to as GL-1 and GL-2, investigated the safety and efficacy of incobotulinumtoxinA in the glabellar region; both are currently in press with another journal. Other published studies of incobotulinumtoxinA are also described in depth in this article, including reports on aesthetic indications, diffusion, therapeutic indications, and studies pertaining to the preclinical and clinical pharmacology of incobotulinumtoxinA. Topics addressed include potency variability, mean concentration, stability and dissociation, and endopeptide immunoassay.

Original languageEnglish (US)
JournalAesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Volume33
Issue number1 Suppl
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Esthetics
Safety
Clinical Pharmacology
Neurotoxins
North America
Immunoassay
incobotulinumtoxinA
Therapeutics
alpha-methylhomocysteine thiolactone

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., ... Waldorf, H. A. (2013). IncobotulinumtoxinA in clinical literature. Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, 33(1 Suppl). https://doi.org/10.1177/1090820X12474635

IncobotulinumtoxinA in clinical literature. / Lorenc, Z. Paul; Kenkel, Jeffrey M.; Fagien, Steven; Hirmand, Haideh; Nestor, Mark S.; Sclafani, Anthony P.; Sykes, Jonathan M; Waldorf, Heidi A.

In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, Vol. 33, No. 1 Suppl, 03.2013.

Research output: Contribution to journalArticle

Lorenc, ZP, Kenkel, JM, Fagien, S, Hirmand, H, Nestor, MS, Sclafani, AP, Sykes, JM & Waldorf, HA 2013, 'IncobotulinumtoxinA in clinical literature.', Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, vol. 33, no. 1 Suppl. https://doi.org/10.1177/1090820X12474635
Lorenc, Z. Paul ; Kenkel, Jeffrey M. ; Fagien, Steven ; Hirmand, Haideh ; Nestor, Mark S. ; Sclafani, Anthony P. ; Sykes, Jonathan M ; Waldorf, Heidi A. / IncobotulinumtoxinA in clinical literature. In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery. 2013 ; Vol. 33, No. 1 Suppl.
@article{fff8753a6d3742dfa9c7f99f227f1d24,
title = "IncobotulinumtoxinA in clinical literature.",
abstract = "IncobotulinumtoxinA is the third neurotoxin type A to be approved for aesthetic use in the United States. Because incobotulinumtoxinA has been in use in Europe for some time, the clinical literature is fairly replete with references to its properties and characteristics, as well as its safety and efficacy. In North America, 2 pivotal trials, referred to as GL-1 and GL-2, investigated the safety and efficacy of incobotulinumtoxinA in the glabellar region; both are currently in press with another journal. Other published studies of incobotulinumtoxinA are also described in depth in this article, including reports on aesthetic indications, diffusion, therapeutic indications, and studies pertaining to the preclinical and clinical pharmacology of incobotulinumtoxinA. Topics addressed include potency variability, mean concentration, stability and dissociation, and endopeptide immunoassay.",
author = "Lorenc, {Z. Paul} and Kenkel, {Jeffrey M.} and Steven Fagien and Haideh Hirmand and Nestor, {Mark S.} and Sclafani, {Anthony P.} and Sykes, {Jonathan M} and Waldorf, {Heidi A.}",
year = "2013",
month = "3",
doi = "10.1177/1090820X12474635",
language = "English (US)",
volume = "33",
journal = "Aesthetic Surgery Journal",
issn = "1090-820X",
publisher = "SAGE Publications Inc.",
number = "1 Suppl",

}

TY - JOUR

T1 - IncobotulinumtoxinA in clinical literature.

AU - Lorenc, Z. Paul

AU - Kenkel, Jeffrey M.

AU - Fagien, Steven

AU - Hirmand, Haideh

AU - Nestor, Mark S.

AU - Sclafani, Anthony P.

AU - Sykes, Jonathan M

AU - Waldorf, Heidi A.

PY - 2013/3

Y1 - 2013/3

N2 - IncobotulinumtoxinA is the third neurotoxin type A to be approved for aesthetic use in the United States. Because incobotulinumtoxinA has been in use in Europe for some time, the clinical literature is fairly replete with references to its properties and characteristics, as well as its safety and efficacy. In North America, 2 pivotal trials, referred to as GL-1 and GL-2, investigated the safety and efficacy of incobotulinumtoxinA in the glabellar region; both are currently in press with another journal. Other published studies of incobotulinumtoxinA are also described in depth in this article, including reports on aesthetic indications, diffusion, therapeutic indications, and studies pertaining to the preclinical and clinical pharmacology of incobotulinumtoxinA. Topics addressed include potency variability, mean concentration, stability and dissociation, and endopeptide immunoassay.

AB - IncobotulinumtoxinA is the third neurotoxin type A to be approved for aesthetic use in the United States. Because incobotulinumtoxinA has been in use in Europe for some time, the clinical literature is fairly replete with references to its properties and characteristics, as well as its safety and efficacy. In North America, 2 pivotal trials, referred to as GL-1 and GL-2, investigated the safety and efficacy of incobotulinumtoxinA in the glabellar region; both are currently in press with another journal. Other published studies of incobotulinumtoxinA are also described in depth in this article, including reports on aesthetic indications, diffusion, therapeutic indications, and studies pertaining to the preclinical and clinical pharmacology of incobotulinumtoxinA. Topics addressed include potency variability, mean concentration, stability and dissociation, and endopeptide immunoassay.

UR - http://www.scopus.com/inward/record.url?scp=84882982343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882982343&partnerID=8YFLogxK

U2 - 10.1177/1090820X12474635

DO - 10.1177/1090820X12474635

M3 - Article

C2 - 23515196

AN - SCOPUS:84882982343

VL - 33

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 1 Suppl

ER -